The trading price of Coherus BioSciences, Inc. (NASDAQ:CHRS) closed lower on Tuesday, Jan 12, closing at $17.58, -1.08% lower than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $17.31 and $17.94. The company’s P/E ratio in the trailing 12-month period was 8.62, while its 5Y monthly beta was 1.37. In examining the 52-week price action we see that the stock hit a 52-week high of $23.03 and a 52-week low of $10.86. Over the past month, the stock has suffered -3.01% in value.
Coherus BioSciences, Inc., whose market valuation is $1.23 Billion at the time of this writing, is expected to release its quarterly earnings report Feb 25, 2021- Mar 01, 2021. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by $0.23 per share this quarter, however they have predicted annual earnings per share of $1.72 for 2021 and $1.06 for 2022. It means analysts are expecting annual earnings per share growth of 0.4% this year and -0.38% next year.
Analysts have forecast the company to bring in revenue of $114.89 Million for the quarter, with the likely lows of $109.6 Million and highs of $119.23 Million. The average estimate suggests sales will likely down by -7.2% this quarter compared to what was recorded in the comparable quarter last year. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2021 is $480.61 Million. The company’s revenue is forecast to grow by +35% over what it did in 2020.
On the technical side, indicators suggest CHRS has a 100% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Sell, while an average of long term indicators suggests that the stock is currently 50% Sell.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned CHRS a recommendation rating is 10. Out of them, 1 rate it a Hold, while 8 recommend Buy, whereas 1 assign an Outperform rating. None analyst(s) have tagged Coherus BioSciences, Inc. (CHRS) as Underperform, while not any of them advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
If we dig deeper into the stock’s outlook, we see that the stock’s PEG is 3.92, which symbolizes a positive outlook. A quick review shows that CHRs price is currently -0.29% off the SMA20 and -2.26% off the SMA50. The RSI metric on the 14-day chart is currently showing 47.69, and weekly volatility stands at 4.37%. When measured over the past 30 days, the indicator reaches 4.02%. Coherus BioSciences, Inc. (NASDAQ:CHRS)’s beta value is currently sitting at 1.37, while the Average True Range indicator is currently displaying 0.69. With analysts defining $19-$35 as the low and high price targets, we arrive at a consensus price target of $29.9 for the trailing 12-month period. The current price is about 9.26% off the estimated low and 101.27% off the forecast high, based on this estimate. Investors will be thrilled if CHRs share price rises to $30, which is the median consensus price. At that level, CHRs share price would be +72.51% above current price.
To see how Coherus BioSciences, Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: CHRS stock’s performance was -1.08% in the latest trading, and 0% in the past year, while Bristol-Myers Squibb Company (BMY) has traded +0.71% on the day and positioned -1.09% lower than it was a year ago. Another comparable company Amgen Inc (AMGN) saw its stock close -0.41% lower in the most recent trading session but was down -0.14% in a year. Furthermore, Gilead Sciences Inc (GILD) showed a decline of -1.08% on the day while its price kept declining at 0% over the past year. Coherus BioSciences, Inc. has a P/E ratio of 8.62, compared to Bristol-Myers Squibb Company’s 0 and Amgen Inc’s 19.08. Also in last trading session, the S&P 500 Index has surged 0.04%, while the Dow Jones Industrial also saw a positive session, up +0.19% on the day.
An evaluation of the daily trading volume of Coherus BioSciences, Inc. (NASDAQ:CHRS) indicates that the 3-month average is 869.68 Million. However, this figure has declined over the past 10 days to an average of 1.33 Million.
Currently, records show that 72.05 Million of the company’s shares remain outstanding. According to Thomson Reuters data, insiders hold 1.62% of outstanding shares, whereas institutions hold 125.64%. The stats also highlight that short interest as of December 14, 2020, stood at 14.6 Million shares, resulting in a short ratio of 21.13 at that time. From this, we can conclude that short interest is 20.27% of the company’s total outstanding shares. It is noteworthy that short shares in December were down slightly from the previous month’s figure, which was 15.76 Million. However, since the stock’s price has seen +0.06% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.
Even if you’re not actively in crypto, you deserve to know what’s actually going on..
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets are already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.